|
1
|
Shivaswamy V, Boerner B and Larsen J:
Post-transplant diabetes mellitus: Causes, treatment, and impact on
outcomes. Endocr Rev. 37:37–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang X, Hu YC, Zhang RY, Jin DX, Jiang Y,
Zhang HN and Cong HL: Effect of cyclosporin A intervention on the
immunological mechanisms of coronary heart disease and restenosis.
Exp Ther Med. 12:3242–3248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhat M, Pasini E, Copeland J, Angeli M,
Husain S, Kumar D, Renner E, Teterina A, Allard J, Guttman DS and
Humar A: Impact of immunosuppression on the metagenomic composition
of the intestinal microbiome: A systems biology approach to
post-transplant diabetes. Sci Rep. 7:102772017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Azzi JR, Sayegh MH and Mallat SG:
Calcineurin inhibitors: 40 years later, can't live without. J
Immunol. 191:5785–5791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Langsford D and Dwyer K: Dysglycemia after
renal transplantation: Definition, pathogenesis, outcomes, and
implications for management. World J Diabetes. 6:1132–1151. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montero N and Pascual J: Immunosuppression
and Post-transplant Hyperglycemia. Curr Diabetes Rev. 11:144–154.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Palepu S and Prasad GV: New-onset diabetes
mellitus after kidney transplantation: Current status and future
directions. World J Diabetes. 6:445–455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Øzbay LA, Smidt K, Mortensen DM, Carstens
J, Jørgensen KA and Rungby J: Cyclosporin and tacrolimus impair
insulin secretion and transcriptional regulation in INS-1E
beta-cells. Br J Pharmacol. 162:136–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pereira MJ, Palming J, Rizell M, Aureliano
M, Carvalho E, Svensson MK and Eriksson JW: Cyclosporine A and
tacrolimus reduce the amount of GLUT4 at the cell surface in human
adipocytes: Increased endocytosis as a potential mechanism for the
diabetogenic effects of immunosuppressive agents. J Clin Endocrinol
Metab. 99:E1885–E1894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bai Y, Wei Y, Wu L, Wei J, Wang X and Bai
Y: C/EBP β mediates endoplasmic reticulum stress regulated
inflammatory response and extracellular matrix degradation in
LPS-stimulated human periodontal ligament cells. Int J Mol Sci.
17:3852016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu M, Wright J, Guo H, Xiong Y and Arvan
P: Proinsulin entry and transit through the endoplasmic reticulum
in pancreatic beta cells. Vitam Horm. 95:35–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozawa S, Katsuta H, Suzuki K, Takahashi K,
Tanaka T, Sumitani Y, Nishida S, Yoshimoto K and Ishida H:
Estimated proinsulin processing activity of prohormone convertase
(PC) 1/3 rather than PC2 is decreased in pancreatic β-cells of type
2 diabetic patients. Endocr J. 61:607–614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Yuan Q, Tang W, Gu J, Osei K and
Wang J: Substrate-favored lysosomal and proteasomal pathways
participate in the normal balance control of insulin precursor
maturation and disposal in β-cells. PLoS One. 6:e276472011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim G, Kim JY and Choi HS: Peptidyl-prolyl
cis/trans isomerase NIMA-interacting 1 as a therapeutic target in
hepatocellular carcinoma. Biol Pharm Bull. 38:975–979. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren LQ, Liu W, Li WB, Liu WJ and Sun L:
Peptidylprolyl cis/trans isomerase activity and molecular evolution
of vertebrate cyclophilin A. Yi Chuan. 38:736–745. 2016.PubMed/NCBI
|
|
16
|
Humbert MV, Mendoza Almonacid HL, Jackson
AC, Hung MC, Bielecka MK, Heckels JE and Christodoulides M: Vaccine
potential of bacterial macrophage infectivity potentiator
(MIP)-like peptidyl prolyl cis/trans isomerase (PPIase) proteins.
Expert Rev Vaccines. 14:1633–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cho KI, Orry A, Park SE and Ferreira PA:
Targeting the cyclophilin domain of Ran-binding protein 2 (Ranbp2)
with novel small molecules to control the proteostasis of STAT3,
hnRNPA2B1 and M-opsin. ACS Chem Neurosci. 6:1476–1485. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ernst K, Langer S, Kaiser E, Osseforth C,
Michaelis J, Popoff MR, Schwan C, Aktories K, Kahlert V, Malesevic
M, et al: Cyclophilin-facilitated membrane translocation as
pharmacological target to prevent intoxication of mammalian cells
by binary clostridial actin ADP-ribosylated toxins. J Mol Biol.
427:1224–1238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tafazoli A: Cyclosporine use in
hematopoietic stem cell transplantation: Pharmacokinetic approach.
Immunotherapy. 7:811–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z and Zhang L: Treatment effect of
cyclosporine A in patients with painful bladder
syndrome/interstitial cystitis: A systematic review. Exp Ther Med.
12:445–450. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J and Osei K: Proinsulin maturation
disorder is a contributor to the defect of subsequent conversion to
insulin in β-cells. Biochem Biophys Res Commun. 411:150–155. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Chen Y, Yuan Q, Tang W, Zhang X
and Osei K: Control of precursor maturation and disposal is an
early regulative mechanism in the normal insulin production of
pancreatic β-cells. PLoS One. 6:e194462011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan Q, Tang W, Zhang X, Hinson JA, Liu C,
Osei K and Wang J: Proinsulin atypical maturation and disposal
induces extensive defects in mouse Ins2+/Akita β-cells. PLoS One.
7:e350982012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu Z, Gilbert ER and Liu D: Regulation of
insulin synthesis and secretion and pancreatic Beta-cell
dysfunction in diabetes. Curr Diabetes Rev. 9:25–53. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan JY, Luzuriaga J, Maxwell EL, West PK,
Bensellam M and Laybutt DR: The balance between adaptive and
apoptotic unfolded protein responses regulates β-cell death under
ER stress conditions through XBP1, CHOP and JNK. Mol Cell
Endocrinol. 413:189–201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu C, Cui S, Zong C, Gao W, Xu T, Gao P,
Chen J, Qin D, Guan Q, Liu Y, et al: The orphan nuclear receptor
NR4A1 protects pancreatic β-cells from endoplasmic reticulum (ER)
stress-mediated apoptosis. J Biol Chem. 290:20687–20699. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwak HJ, Choi HE, Jang J, Park SK, Bae YA
and Cheon HG: Bortezomib attenuates palmitic acid-induced ER
stress, inflammation and insulin resistance in myotubes via AMPK
dependent mechanism. Cell Signal. 28:788–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oh YS, Lee YJ, Kang Y, Han J, Lim OK and
Jun HS: Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β
cells via regulation of SREBP1c and C/EBPβ transcription factors. J
Endocrinol. 216:343–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cumaoglu A, Arıcıoglu A and Karasu C:
Redox status related activation of endoplasmic reticulum stress and
apoptosis caused by 4-hydroxynonenal exposure in INS-1 cells.
Toxicol Mech Methods. 24:362–367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reid DW, Chen Q, Tay AS, Shenolikar S and
Nicchitta CV: The unfolded protein response triggers selective mRNA
release from the endoplasmic reticulum. Cell. 158:1362–1374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
